Revenue ($USD): $6,939,900,000
R&D spend: $406,000,000.00
Employees: 18,000
Fiscal year end: 12/31/22
CEO: Ivan Tornos
DuringZB’s Q2 2023 earnings call前首席执行官Bryan Hanson (who'sjoining 3M's healthcare spinoff as CEO) noted that Zimmer Biomet has 40 planned product launches between this year and the end of 2025, the majority in 4%-plus growth markets. For example, ZB officials said they plan a full market release of their Persona IQ smart knee implant by Q1 2024, and they still expect to be first-to-market with a robotic shoulder surgery application with their Rosa platform.
Zimmer Biomet continues toenhance its ZBEdge Dynamic Intelligence platform for hip and knee surgeries. In March, it announced a definitive agreement toacquire Ossis, a maker of personalized 3D-printed implants.–CN